Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy

• Study of 119 women who have undergone risk-reducing salpingo-oophorectomy (RRSO)
• The prevalence of female sexual dysfunction (FSD) after RRSO was 74%.
• The prevalence of hypoactive sexual desire disorder (HSDD) after RRSO was 73%.
• Significant factors were relationship satisfaction, bodily pain, and vaginal estrogen.
• Serum testosterone and free androgen index are not associated with sexual function.

ObjectivesTo determine the prevalence of sexual dysfunction in women after risk-reducing salpingo-oophorectomy (RRSO) and to assess factors which may influence sexual wellbeing following this procedure.MethodsThis work is a cross-sectional study of women who underwent RRSO at a tertiary gynecologic oncology unit between January 2009 and October 2014. Data collection involved a comprehensive questionnaire including validated measures of sexual function, sexual distress, relationship satisfaction, body image, impact of event, menopause specific quality of life, and general quality of life. Participants were invited to undergo blood testing for serum testosterone and free androgen index (FAI).Results119 of the 206 eligible women participated (58%), with a mean age of 52 years. The prevalence of female sexual dysfunction (FSD) was 74% and the prevalence of hypoactive sexual desire disorder (HSDD) was 73%. Common sexual issues experienced included; lubrication difficulty (44%), reduced sexual satisfaction (41%), dyspareunia (28%) and orgasm difficulty (25%). Relationship satisfaction, the use of topical vaginal estrogen and lower generalized body pain were significantly associated with a decreased likelihood of sexual dysfunction. Serum testosterone, FAI, the use of systemic hormone replacement therapy (HRT), prior history of breast cancer, menopausal status at the time of surgery and hysterectomy did not correlate with sexual dysfunction.ConclusionThe prevalence of FSD and HSDD after RRSO was 74% and 73% respectively. Relationship satisfaction, low bodily pain and use of topical vaginal estrogen were associated with a lower likelihood of sexual dysfunction. There was no correlation between serum testosterone or FAI, and sexual dysfunction.